Fig. 2: Clinical evaluations and imaging procedures of the patients over time. | Nature Communications

Fig. 2: Clinical evaluations and imaging procedures of the patients over time.

From: Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern—case reports

Fig. 2

The temporal relationship between the time points of the clinical assessments (motor function test: UPDRS part III or MDS-UPDRS part III; cognitive function test: MOCA; olfactory function test: TDI sum-score) and the time points of the imaging procedures (DAT-SPECT, FDG-PET) is illustrated. The red-shaded area indicates therapy with Acetyl-DL-Leucine (5 g/day). Results of the clinical ratings are presented for patient 1 (a) and patient 2 (b). Note: during the study, the motor function assessment in patient 1 was switched from UPDRS III to MDS-UPDRS III. Motor scores are presented without the item action tremor, which does not belong to the cardinal motor signs of Parkinson’s disease. Time points of the imaging procedures are indicated as icons. Results of the imaging procedures are presented in Fig. 3 and Table 1. Source data are provided as a Source Data file.

Back to article page